Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 3/20 | 0.43 |
| ▸ | CLK2 | P49760 | 3/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.43 |
| ▸ | CLK3 | P49761 | 2/20 | 0.43 |
| ▸ | IGF1R | P08069 | 12/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15208658 | 0.92 | CLK1 (0.43) | CLK1CLK2DYRK1ACLK4DYRK1B | |
| SCHEMBL15208562 | 0.84 | CCNT1 (0.41) | IGF1RNTRK1 | |
| SCHEMBL15210049 | 0.82 | NTRK1 (0.38) | IGF1RNTRK1 | |
| SCHEMBL15059707 | 0.82 | IGF1R (0.38) | IGF1RNTRK1 | |
| SCHEMBL2319961 | 0.81 | IGF1R (0.59) | IGF1RNTRK1 | |
| SCHEMBL15208435 | 0.81 | PDE5A (0.41) | IGF1RNTRK1 | |
| SCHEMBL15059562 | 0.80 | ROCK2 (0.41) | IGF1RNTRK1 | |
| SCHEMBL15058709 | 0.80 | IGF1R (0.54) | IGF1RNTRK1CDK2 | |
| SCHEMBL15209627 | 0.79 | PAK3 (0.43) | IGF1RNTRK1 | |
| SCHEMBL15059672 | 0.78 | PAK1 (0.61) | IGF1RNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2748159-A1 | SERINE/THREONINE PAK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013026914-A1 | SERINE/THREONINE PAK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | CLK1 794/4885CLK2 691/4885DYRK1A 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.